Published in final edited form as:

Biochim Biophys Acta. 2017 October ; 1862(10 Pt B): 1166–1177. doi:10.1016/j.bbalip.2017.06.006.

Establishing the lipid droplet proteome: Mechanisms of lipid droplet protein targeting and degradation

Kirill Bersuker and James A. Olzmann*

Department of Nutritional Sciences and Toxicology, University of California, Berkeley, CA 94720 USA

Abstract

Lipid droplets (LDs) are ubiquitous, endoplasmic reticulum (ER)-derived organelles that mediate the sequestration of neutral lipids (e.g. triacylglycerol and sterol esters), providing a dynamic cellular storage depot for rapid lipid mobilization in response to increased cellular demands. LDs have a unique ultrastructure, consisting of a core of neutral lipids encircled by a phospholipid monolayer that is decorated with integral and peripheral proteins. The LD proteome contains numerous lipid metabolic enzymes, regulatory scaffold proteins, proteins involved in LD clustering and fusion, and other proteins of unknown function. The function of LDs is inherently determined by the composition of its proteome and alteration of the LD protein coat provides a powerful mechanism to adapt LDs to fluctuating metabolic states. Here, we review the current understanding of the molecular mechanisms that govern LD protein targeting and degradation.

1. Introduction

Lipid droplets (LDs) are highly conserved, ubiquitous organelles that function as cellular hubs of lipid metabolism [1–3]. Although the mechanisms of LD biogenesis remain incompletely understood, emerging data indicates that LDs are endoplasmic reticulum (ER)-derived organelles [1–3]. The most widely proposed model suggests that neutral lipids (e.g. triacylglycerol [TAG] and cholesterol esters) are deposited between the leaflets of the ER bilayer forming a “lens” structure, and the LD subsequently buds into the cytoplasm from the outer leaflet of the ER [1–3]. The mature cytoplasmic LDs may remain in contact with the ER and/or associate with other organelles in the cell [4]. LDs serve diverse cellular functions, including sequestering toxic lipids [5,6] and acting as dynamic lipid storage depots that enable rapid mobilization of fatty acids for energy [7,8], membrane biosynthesis [9–11], and lipid signaling pathways [12,13]. Notably, dysregulation of LD homeostasis has been implicated in the pathogenesis of numerous diseases [14,15], including diseases associated with an excess of LDs (e.g. obesity, diabetes, and cardiovascular disease) and with a deficiency of LDs (e.g. lipodystrophy and cachexia).

*Address correspondence to: James A. Olzmann, olzmann@berkeley.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

LDs have a unique ultrastructure, consisting of a central core of neutral lipids encircled by a phospholipid monolayer that is decorated with integral and peripheral proteins [16]. The functions of LDs are intrinsically connected to the composition of the LD proteome, which contains proteins that mediate lipid synthesis and degradation, integrate nutrient signals, and facilitate LD clustering and fusion [17,18]. Regulated alteration of the LD proteome provides a useful mechanism for homeostatic adaptation of LD functions in response to fluctuations in the cellular demand for lipids and energy. Here, we review the current understanding of the molecular mechanisms that govern LD protein targeting and degradation.

2. Establishing the LD proteome

2.1. Challenges in defining the composition of the LD proteome

An accurate inventory of LD proteins is essential for understanding LD functions. The protein composition of LD-enriched buoyant fractions isolated from many species and cell types has been extensively analyzed by proteomics [19–39]. However, this method yields many false positives due to contamination of buoyant fractions with co-fractionating organelles or membrane remnants, which likely reflects physical associations of LDs with the ER [40–44], mitochondria [7,8,45], peroxisomes [46,47], and early endosomes [48]. Indeed, abundant ER proteins (e.g. BiP, Grp94, and PDI) are common contaminants identified in LD proteomic experiments. The most stringent studies analyzing LD proteomes applied a quantitative protein correlation profiling strategy to identify 111 high confidence LD proteins in oleate-treated *Drosophila* S2 cells [49] and 35 high confidence LD proteins in yeast grown to stationary phase [20]. However, LD proteins present in other organelles in addition to LDs (i.e. dual localization) may not be designated as LD proteins using this approach.

Efforts to define the LD proteome are also complicated by the heterogeneity of LDs, including differences in LD size, function, organelle association, and lipid composition [50]. This heterogeneity in LDs is lost when LDs are purified in bulk for proteomics analysis. A recent study addressed this limitation by further separating bulk buoyant fractions with additional rounds of differential centrifugation, yielding fractions enriched in LDs that differed in size [51]. Interestingly, different sized LDs exhibited differences in their protein composition, association with co-purifying organelles, membrane phospholipid content, and enzymatic activity for phospholipid synthesis *in vitro* [51]. Heterogeneity in the LD proteome composition arises in part from the ordered LD proteome remodeling that occurs during LD biogenesis, maturation, and degradation. For example, treatment of differentiated 3T3-L1 adipocytes with oleate established a temporal gradient of distinct LD subpopulations marked by members of the perilipin (PLIN) family of LD coat proteins, including small PLIN3 and PLIN4-positive LDs, intermediate PLIN2-positive LDs, and large PLIN1-positive LDs [52]. The sequential recruitment of proteins to emerging LDs has also been observed by time-lapse fluorescence microscopy using fluorescent markers of nascent LDs [53]. While long chain acyl-CoA synthetase 3 (ACSL3) was constitutively present at sites of LD biogenesis in the ER, PLIN2 and PLIN3 were recruited to these sites with a delay following the addition of oleate [53]. Alterations in the metabolic state of the cell can induce

functional specialization of existing LDs through the regulated recruitment of effector proteins, such as the recruitment of the TAG-synthesis enzyme glycerol-3-phosphate acyltransferase 4 [GPAT4] to a subpopulation of LDs for LD growth [40] and the recruitment of Rab18 for LD degradation [54,55]. Differences in LD lipid composition can also impact the composition of the associated proteomes (e.g. cholesterol ester-rich versus TAG-rich LDs [39,56]). Finally, the co-fractionation of ER and other organelles with specific populations of differentially sized LDs [51] raises the possibility that differences in LD proteome composition may determine which LDs associate with other organelles, potentially by facilitating the formation of unique membrane contact sites. Thus, given the heterogeneity of LDs, it is important to note that the associated LD proteome may differ depending on the metabolic state of the cell, the biogenesis stage of the LD, and the LD function.

Despite the complications involved in defining the LD proteome, many proteins identified in buoyant fractions have been confirmed to localize to LDs by fluorescence and/or electron microscopy. General classes of validated LD proteins include, but are not limited to, regulatory scaffold proteins (PLIN1-5), TAG biosynthetic enzymes (ACSL3, GPAT4, 1-acylglycerol-3-phosphate O-acyltransferase 3 [AGPAT3], phosphatidic acid phosphatase [PAP], diacylglycerol O-acyltransferase 2 [DGAT2]), TAG lytic machinery (adipose triglyceride lipase [ATGL], comparative gene identification 58 [CGI-58], G0/G1 switch gene 2 [G0S2], hormone-sensitive lipase [HSL]), ubiquitination factors (UBX domain-containing protein 8 [UBXD8], ancient ubiquitous protein 1 [AUP1], ubiquitin-conjugating enzyme E2 G2 [UBE2G2]), and Ras-related proteins (Rab8a, Rab18). Cell types that exhibit large LDs often express additional proteins that mediate LD fusion (Cell death activators CIDEA and CIDEA [FSP27] in adipocytes). A future challenge is to develop novel methods to accurately identify LD proteins in heterogeneous populations of LDs and to quantify changes in the composition of the LD proteome under different metabolic states.

2.2. Structural elements involved in protein association with LDs

The ultrastructure of the LD imposes biophysical constraints on the type of protein domains that can associate with LDs. The hydrophobic neutral lipid core of LDs is an energetically unfavorable environment for hydrophilic protein domains. As a consequence, the interior of the LD is devoid of proteins, and integral LD proteins associate with the phospholipid monolayer by adopting monotopic conformations. These conformations can be broadly categorized into two classes: proteins that associate with the membrane through hydrophobic domains (Class I) or amphipathic helices (Class II) [57] (Fig. 1). Although the organization of LD proteins into different classes (Class I and Class II) is a generalization and the actual structures that these proteins adopt within membranes are not known, this terminology provides a useful conceptual framework for discussing how proteins associate with the LD membrane.

LD proteins that contain hydrophobic domains (Class I) frequently adopt a hairpin topology, which is defined by a membrane-embedded internal hydrophobic segment that is flanked by cytosolically-accessible, hydrophilic N- and C- termini. Examples of Class I hairpin proteins that traffic from the ER to LDs include UBXD8 [58,59], AUP1 [60], caveolin-1 [61,62],

DGAT2 [63], and GPAT4 [40]. A common feature of many of these hairpin domains is a conserved proline residue positioned in the center of the hydrophobic region. It has been hypothesized that this proline generates a sharp turn in the protein structure, facilitating the formation of an antiparallel helix or β -strand conformation [64,65]. Consistent with the significance of these proline residues, mutation of a triad of prolines in plant oleosin (often referred to as the “proline knot”) abolished its localization at LDs and confined oleosin to the ER [64–66]. Similarly, mutation of two prolines in the hepatitis C viral core protein [66] or a proline-valine-glycine sequence in AUP1 [51] prevented their trafficking from the ER to LDs. Mutations of the proline knot in oleosin did not impact its topology [64], but mutation of the proline-valine-glycine sequence in AUP1 [51] or the central proline residue in caveolin-1 [67] converted them into single-pass transmembrane proteins, indicating that these residues can play a critical role in determining the final topology. However, a proline within the hydrophobic region is not an absolute requirement for trafficking of Class I proteins to LDs. Mutation of a central proline residue in the hydrophobic regions of AAM-B, ALDI, and CYB5R3 did not affect their LD localization [68]. The hydrophobic regions of these proteins are at their extreme N-termini, raising the possibility that the position of the hydrophobic region determines the structure that these regions adopt as well as the importance of the proline. It should be noted that while the hydrophobic region of Class I LD proteins is generally necessary and sufficient for LD targeting, trafficking of some proteins from the ER to LDs is impacted by flanking positively-charged sequences [60,62]. The significance of these regions is unclear, but they may mediate interactions with specific negatively charged lipid headgroups or proteins in the LD monolayer.

A second major class of LD proteins (Class II) associates with the LD membrane via amphipathic helices. Examples include CTP:phosphocholine cytidyltransferase (CCT) [69,70], CIDEA [71], the perilipin family of proteins [72], and the antiviral protein viperin [73]. The mechanism by which Class II proteins selectively target the LD membrane, as opposed to other cellular membranes, is an active area of investigation. Current models propose that amphipathic helices within Class II proteins confer the ability to “sense” certain properties of the LD membrane. Indeed, emerging findings suggest that distinct physiochemical properties of organelle membranes can specify the types of proteins motifs that can bind to them [74]. In contrast to the membranes of the plasma membrane and later portions of the secretory pathway, the ER and LD membranes are characterized by low levels of negatively charged phospholipids (e.g. phosphatidylserine) and a high degree of lipid packing defects, caused by the presence of unsaturated fatty acids and the general lack of cholesterol [74]. The amphipathic helix of CCT, the rate-limiting enzyme in phosphatidylcholine synthesis, and its association with membranes have been studied in detail [75]. Consistent with an important role for lipid packing in conferring binding specificity to LD proteins, CCT is activated by binding to membranes that contain high levels of lipids with smaller headgroups (e.g. diacylglycerol and phosphatidylethanolamine), which have a conical shape that increases lipid packing defects and membrane curvature strain [65–68]. In solution, CCT’s amphipathic helix binds to its active site and inhibits its activity [75]. Insertion of the amphipathic helix into a membrane exhibiting packing defects, such as a membrane with low levels of phosphatidylcholine, anchors CCT to the membrane and relieves the helix-mediated autoinhibition of its enzymatic activity [75]. Coupling of

CCT activation to membrane binding provides an elegant feedback mechanism that regulates LD size [69,70,76]. In *Drosophila* S2 cells, CCT relocates from the nucleus to LDs during LD expansion, when levels of phosphatidylcholine in the LD monolayer become limiting [69,70,76]. Binding of CCT to LDs increased synthesis of phosphatidylcholine at the monolayer, which reduced membrane surface tension and prevented fusion between LDs [69,70,76]. In contrast to *Drosophila*, mammalian cells contain two CCT isoforms, CCT α and CCT β . CCT α was recruited to the surface of expanding LDs in murine macrophages [69], suggesting that the role of CCT in LD growth is conserved from insects to mammals. However, a recent study found that while CCT α activity was important for LD expansion, CCT α was not recruited to LDs in differentiating 3T3-L1 adipocytes or a wide variety of non-adipocyte cell types incubated with oleate [77]. One explanation that was proposed for these apparent contradictory results is that *Drosophila* S2 cells have significantly different phosphatidylcholine: phosphatidylethanolamine ratios, resulting in more recruitment of CCT to LDs during LD expansion [77]. Irrespective of the site of CCT action, the subsequent and final step in phosphatidylcholine synthesis is mediated by choline phosphotransferase (hCPT1, Golgi localized) or choline/ethanolamine phosphotransferase 1 (hCEPT, ER and nuclear envelope localized) [78].

Perilipins are another important family of Class II LD proteins that integrate nutrient signals and control lipid storage in LDs [79]. PLIN1 is translated by cytosolic free ribosomes [72,80,81] and thought to be directly inserted into LD membranes. It is generally assumed that all perilipins are translated in the cytosol and directly targeted to LDs, but experimental evidence is lacking. The perilipins can compete with each other for LD localization [79,82], indicating that sites for their insertion and/or association with LDs are limited. A conserved series of 11-mer repeats in the perilipins form an extended amphipathic helix that is sufficient for recruitment to LDs [72]. Mutations in this region that affect the amphipathic nature or helix register significantly reduce LD localization [72]. Most perilipins also contain a C-terminal helical bundle that is analogous to the receptor-binding region of apolipoprotein E [72,83]. This region contains a deep hydrophobic cleft that may bind specific lipids and contribute to LD localization under certain conditions [72,83].

Although hydrophobic hairpins and amphipathic helices are the most common motifs that target proteins to droplets, other mechanisms have been described (Fig. 1). ELMOD2 [84] and SNAP-23 [85] are anchored to droplets through a palmitate group. Since palmitoylation is a reversible, post-translational modification, it is possible that the LD localization of these proteins could be controlled by the addition and/or removal of palmitate. Another alternative LD targeting mechanism is utilized by the ATGL activator CGI-58, which employs a unique membrane-embedded motif [86]. Solution state NMR of a CGI-58 peptide embedded in a dodecylphosphocholine micelle indicates that this region of CGI-58 forms a hydrophobic core consisting of two short arms containing critical tryptophan residues, mutation of which abolishes LD localization in cells [86]. Finally, several proteins are recruited to LDs through direct interactions with Class I and II LD proteins. Examples include recruitment of UBE2G2 by the UBE2G2-binding motif of AUP1 [87,88], VCP by the UBX domain of UBXD8 [59,89], and HSL by the phosphorylated N-terminus of PLIN1 [90,91].

2.3. Insertion of LD proteins into the ER

Most, if not all, Class I LD proteins that have been studied exhibit dual ER and LD localization. During LD biogenesis, Class I proteins inserted into the ER have been proposed to traffic to nascent LDs by diffusing within the outer leaflet of the ER membrane, which is likely contiguous with the monolayer of forming LDs [53] (Fig 1). Proteins can also traffic from the ER to mature LDs through membrane bridges that link the two organelles [40]. The canonical pathways for insertion of proteins into the ER membrane [92–95] include: 1) the signal recognition particle (SRP) pathway, which mediates co-translational insertion of proteins bearing N-terminal signal sequences or transmembrane domains through the Sec61 translocon, and 2) the guided entry of tail-anchored proteins (GET) pathway, which mediates posttranslational insertion of proteins bearing C-terminal transmembrane domains. Compared to well-characterized SRP and GET pathway substrates, insertion of Class I hairpin proteins poses a unique biophysical challenge and may require a different set of insertion machinery. However, the insertion of caveolin-1 into rough microsomes *in vitro* and the insertion of heterologously expressed oleosin into the ER in yeast required SRP and Sec61 [61,96], suggesting that at least a portion of Class I LD proteins employ the SRP-Sec61 ER insertion pathway (Fig. 2A).

A novel posttranslational ER insertion pathway was recently discovered for the Class I LD protein UBXD8 [97] (Fig. 2B). *In vitro* translated UBXD8 was inserted posttranslationally into purified rough ER microsomes, independently of both the SRP and GET pathways [97]. In cells, insertion of UBXD8 into discrete ER subdomains was mediated by the soluble peroxisome biogenesis factor PEX19, which bound the hairpin of UBXD8 and functioned in concert with its ER membrane receptor PEX3 [97] (Fig. 2B). No insertion of UBXD8 directly into LDs was observed [97], consistent with the model that Class I LD proteins insert first into the ER and then traffic to LDs. Furthermore, insertion of UBXD8 into ER puncta was unaffected by inhibition of acyl-CoA synthetases with triacsin C, suggesting that these puncta are not nascent LDs. Deletion of PEX19, depletion of PEX3, or disruption of the PEX19-PEX3 interaction impaired UBXD8 ER insertion and resulted in aberrant insertion of UBXD8 into mitochondria [97]. Together, these results provide strong evidence that support the importance of the PEX19-PEX3 pathway for mediating insertion of hairpin proteins such as UBXD8, and potentially other Class I proteins, into the ER. The UBXD8 hydrophobic region is composed of ~20 amino acids that are predicted by bioinformatic algorithms to form a transmembrane helix. Employing a posttranslational insertion pathway could be one mechanism to ensure that proteins are inserted in a hairpin conformation, rather than an ER-restricted, single-pass transmembrane conformation. Such a pathway could also mediate insertion of hairpin proteins into ER subdomains that lack ribosomes and Sec61 translocation machinery (i.e. smooth ER).

The PEX19-PEX3 pathway also mediates the insertion of a subset of peroxisomal proteins and is required for peroxisome biogenesis [98]. Interestingly, UBXD8 ER insertion required PEX19 farnesylation and strong overexpression of a PEX19 farnesylation-defective mutant resulted in mislocalization of UBXD8 to peroxisomes [97]. Given that the PEX19 farnesylation was found to be dispensable for peroxisome biogenesis [99], farnesylation may function as a master switch that controls the sorting of proteins to LDs and not peroxisomes

[97]. However, a recent study found that PEX19 farnesylation is required for the insertion of a subset of peroxisomal membrane proteins, possibly by inducing a conformational change in PEX19 that increases its affinity for its substrates [100]. Thus, while farnesylation is clearly important for UBXD8 targeting [97], the precise role of PEX19 farnesylation in controlling LD and peroxisome protein sorting is unclear. Given that both LDs and peroxisomes are involved in lipid metabolism, the shared PEX19-PEX3 insertion pathway could provide an important mechanism to coordinate biogenesis or functional crosstalk between the two organelles. Since UBXD8 is the only protein known to employ PEX19-PEX3 for insertion into LDs, it will be important to determine if other LD proteins generally employ this pathway. In addition, a new SRP-independent targeting (SND) co-translational insertion pathway was recently discovered in yeast that inserts a broad range of ER proteins, with an intriguing preference for proteins bearing internal hydrophobic domains [101]. However, the role of SND proteins in mammalian cells and in inserting LD proteins is unknown.

2.4. ER-LD protein sorting: Generating asymmetry in contiguous membranes

The insertion of LD proteins into the ER and the diffusion of proteins between LDs and the ER via membrane bridges present the cell with a fundamental protein sorting challenge. This raises the question as to how the proteomes of these two highly connected organelles are established and maintained. While proteins within the ER lumen are spatially segregated from cytosolic LDs, sorting mechanisms likely control the relative distribution of proteins between contiguous ER and LD membranes. The biophysical properties of the ER phospholipid bilayer and the LD phospholipid monolayer, the latter of which is unable to accommodate bitopic and polytopic ER membrane proteins, likely constitute a primary sorting mechanism. The deposition of TAG between the leaflets of the ER membrane, which forms the LD “lens”, alters the bilayer height and would thus generate asymmetry through its inability to accommodate transmembrane domain-containing proteins, due to hydrophobic mismatch (i.e. a difference in the hydrophobic thickness of the membrane bilayer and the length of the hydrophobic portion of a transmembrane portion). As the LD emerges, a protein topology-selective diffusion barrier would be created by the junction between the ER phospholipid bilayer and LD phospholipid monolayer (Fig. 2C). This junction would permit monotopic proteins, such as Class I proteins, to traffic into the phospholipid monolayer of LDs. In contrast, transmembrane proteins that cannot be physically accommodated in the LD phospholipid monolayer would remain by default in the ER phospholipid bilayer. At the junction of other organelles connected by contiguous membranes there are often proteins that regulate the diffusion barriers to maintain the correct proteomes, such as septin 2 at the junction between the plasma membrane and primary cilium [102] and the nuclear pore complex at the junction between the inner and outer nuclear membranes [103]. Seipin is positioned at ER-LD contact sites [41,42,44,104], but whether seipin or another protein acts as a “gatekeeper” to control protein diffusion between the ER and LDs is unknown.

A diffusion barrier model based solely on topology predicts that Class I proteins would equilibrate between the ER and LDs. However, this prediction is inconsistent with the observed distributions of Class I proteins between the two organelles. Some proteins that

traffic through the ER are enriched almost exclusively in LDs (e.g. AAM-B [68,105] and GPAT4 [40]), while others localize to both ER and LDs (e.g. UBXD8 [89]). This asymmetry in protein distribution may be generated by differences in mobility within a particular organelle, which could be imposed by the preference for a binding partner (or lipid region) that is present exclusively at one organelle and not the other (Fig. 2C). For example, the polytopic ER-resident protein UBAC2 binds to UBXD8 in the ER and blocks its trafficking to LD [89]. This indicates that UBAC2 binding functions as a dominant signal for retention of UBXD8 in the ER. Membrane curvature may also facilitate protein segregation between membranes. Membrane curvature is likely increased at the TAG-rich “lens” structure that forms between the leaflets of the ER at sites of LD biogenesis. The specific lipid composition of membranes and/or the presence of lipid packing defects at these sites may constitute a more favorable environment for LD proteins relative to bulk ER. While this mechanism has not been directly addressed, it has been noted that certain LD proteins, such as ACSL3 and truncated fragments of AAM-B (i.e. HPos) and GPAT4 (i.e. livedrop), become concentrated at LD biogenesis sites in the ER [41,53]. Finally, differences in protein stability may also contribute to the asymmetric distribution of proteins between organelles (Fig. 2C). Many LD proteins are strongly stabilized in cells treated with oleate, suggesting that their stability is increased by insertion into LDs. In addition, degradation of some Class I LD proteins in the ER results in their relative enrichment on LDs [106,107].

Thus, emerging findings support a model in which the proteomes of the contiguous ER and LDs is determined by a topology-selective diffusion barrier as well as by differences in protein mobility and stability between the two organelles. It is possible that targeted insertion of LD proteins into specialized ER subdomains (e.g. PEX19-PEX3-mediated insertion of UBXD8) could also contribute to the enrichment of LD proteomes within specific regions of the ER. Given the heterogeneity in LD proteomes (e.g. GPAT4 trafficking to select LDs), there must be mechanisms to target LDs to select LDs or to remove proteins from select LDs.

3. Connections between LDs and the ubiquitin-proteasome system

3.1. Protein degradation: General concepts in protein quality and quantity control

Protein degradation is essential for maintaining the fidelity and appropriate composition of the cellular proteome [108]. Organelles contain specialized pathways (e.g. ER-associated degradation [ERAD] [109–111]) that mediate the recognition of their respective proteomes for degradation. These include quality control pathways that degrade misfolded and damaged proteins (e.g. mutant proteins involved in human diseases) as well as quantity control pathways that degrade correctly folded, functional proteins in order to regulate cellular processes (e.g. metabolic enzymes such as HMG-CoA Reductase in cholesterol biosynthesis) [109–111]. Covalent modification of substrate proteins with a polyubiquitin chain is the canonical signal that targets substrates to the 26S proteasome for proteolytic degradation [112]. In this pathway, sequential enzymatic reactions performed by an E1 ubiquitin-activating enzyme, an E2 ubiquitin-conjugating enzyme, and an E3 ubiquitin-protein ligase (E3 ligase) conjugate ubiquitin to one or more lysines, the N-terminus, or, in seemingly rare cases, serines or threonines in target proteins [112]. Successive conjugation

of ubiquitin to any of the seven lysines (K6, 11, 27, 29, 33, 48, 63) within the preceding ubiquitin forms structurally distinct polyubiquitin chains that have diverse signaling roles, such as in the regulation of protein interactions, trafficking, and enzymatic activity [101]. K48-linked polyubiquitin chains, and in some cases K11 and K63 linkages, target proteins to the proteasome [101]. Hundreds of E3 ligases and associated adaptor proteins provide specificity to the ubiquitin conjugation reaction, mediating the recognition and ubiquitination of distinct sets of substrates [112]. However, the substrates of the vast majority of E3 ligases have not been elucidated.

3.2. Ubiquitin-dependent degradation of LD proteins

Several LD proteins are degraded by the ubiquitin-proteasome system (UPS) under conditions where the flux of lipids into cells and the overall LD abundance are low (e.g. cells cultured in the absence of fatty acid supplementation) (Table 1). Induction of LD biogenesis with oleate increases the stability of many of these proteins, including the perilipins PLIN1 [113] and PLIN2 [82,114], the TAG lipase ATGL [89,115], the LD fusion mediator FSP27 [116,117], and the ATGL inhibitor G0S2 [118]. Linking the stability of the LD proteome to the formation of LDs is a clever mechanism that enables rapid LD biogenesis in responses to fluctuations in intracellular lipid abundance without the need to initiate compensatory gene expression programs. The clearance of lipolytic proteins under low LD conditions may also be a regulatory mechanism that ensures that TAGs are not hydrolyzed when energy stores are low.

The mechanisms that target LD proteins for degradation are mostly unknown. One possibility is that insertion of LD proteins into the LD monolayer “masks” degrons (i.e. degradation signals) that are recognized by the UPS in the absence of a membrane (Fig. 3). These degrons may also become accessible to UPS machinery when molecular crowding forces LD proteins to disassociate from monolayers, for instance during lipolytic degradation of LDs [119]. Consistent with the “masking” model, deletion of PLIN1 stabilized LD-associated PLIN2 and increased its half-life [82,120], indicating that PLIN2 levels are in part controlled through competition with PLIN1 for limited binding sites on the LD monolayer. Mutation of the N-terminal alanines of PLIN2 stabilized the protein in the absence of LDs, leading the authors to propose that these residues constitute an N-end rule degron [82]. However, whether PLIN2 is degraded via the N-end rule degradation pathway remains to be experimentally determined. Alternatively, disordered amphipathic helices in PLIN1 and PLIN2 could function as degrons in the absence of a monolayer. Indeed, a purified amphipathic helix from PLIN1 is unstructured in solution and only gains α -helical structure when incubated with membranes, and mutations that disrupted PLIN1’s binding to LDs significantly accelerated its degradation in yeast [72]. A degron consisting of a consensus motif that binds to the cytosolic/nuclear E3 ligase COP1 (also known as RFWD2) was recently found in ATGL. In this study, COP1 was proposed to regulate ATGL stability by ubiquitinating at least one lysine in the ATGL patatin-like domain [115]. Degrons may also be masked by high affinity interactions between proteins at the LD surface. Indeed, binding of ATGL to G0S2 [118] and PLIN1 to CGI-58 [120] impaired the proteasomal clearance of their respective binding partners. Thus, in the absence of LDs, exposed degrons may target LD-associated proteins to the proteasome. However, levels of UBXD8 and

AUP1, proteins that are present at LDs and the ER, are not affected by the presence of LDs [89,119], indicating that the relationship between LD abundance and protein stability does not extend to all LD proteins.

The diffusion of proteins between LDs and the ER through extensive contact sites [76] raises the possibility that degradation of some LD proteins may occur in the ER (Fig. 3). Consistent with this possibility, a recent study in yeast demonstrated that hairpin motifs were sufficient to target proteins for degradation through ERAD [106]. ERAD enables the cytosolic degradation of proteins from the early secretory pathway by mediating their recognition, ubiquitination, and subsequent extraction from the ER membrane by the AAA ATPase VCP (Cdc48 in yeast) [109–111]. Deletion of the yeast, polytopic ERAD E3 ligase Doa10p or its cognate E2 ubiquitin-conjugating enzymes Ubc6p or Ubc7p stabilized the Class I LD protein Pgc1p in the ER [106]. Similarly, expression of a temperature sensitive Cdc48 mutant also stabilized Pgc1p [106]. Two additional Class I LD proteins, Dga1p and Yeh1p, were identified as substrates of Doa10p [106]. Intriguingly, a Pgc1p chimera in which the hairpin region was replaced with the heterologous hairpin region from mammalian GPAT4 was similarly unstable in the absence of LDs and degraded through a Doa10p-dependent pathway [106], suggesting that hairpin conformations are recognized as degrons by Doa10p. Together, these data provide the first evidence that ERAD mediates the degradation of LD proteins. An additional mechanism for regulating early steps in LD formation could be the stabilization of machinery necessary for LD growth and budding at predetermined sites. This idea is supported by a study in mammalian cells which demonstrated that overexpressed Class I LD protein DGAT2, a TAG-synthesis enzyme that functions in LD expansion, is degraded through an ERAD pathway that uses the E3 ligase gp78 [107]. These findings support the hypothesis that degradation of LD proteins by ERAD is a mechanism that maintains the composition of the ER proteome, contributes to the relative enrichment of ER proteins at LDs or sites of LD biogenesis, and degrades LD proteins during lipolysis. How general the role of ERAD is in degrading LD proteins is and whether this pathway of LD protein degradation is regulated remains to be determined.

Ubiquitin-dependent degradation of proteins directly from LDs (Fig. 3) is another mechanism that could regulate the composition of the LD proteome. Interestingly, proteins that function in ubiquitination pathways or that contain ubiquitin binding motifs have been observed on LDs (Table 2), raising the possibility that these proteins interact to form a functional LD-associated ubiquitination complex. Several Class I LD proteins recruit soluble ubiquitination factors to the LD surface; UBXD2 and UBXD8 recruit the membrane extraction factor VCP [59,89], AUP1 recruits the E2 ubiquitin-conjugating enzyme UBE2G2 [87,88], and spartin (also known as SPG20) recruits the E3 ligases AIP4 and AIP5 [121–123]. Some of these proteins are functional components (AUP1, UBE2G2, UBXD2, UBXD8, VCP) [124] of multimeric ERAD complexes in the ER and could have analogous functions in LDs. However, whether these factors contribute to the ubiquitination and/or degradation of LD proteins has not been established. Spartin has been reported to mediate the ubiquitination of PLIN2 by recruiting AIP4, as overexpression of wild-type spartin but not spartin lacking an AIP4-interaction motif (PPXY motif) increased ubiquitination of PLIN2 [121]. Whether AIP4 ubiquitination of PLIN2 requires other ubiquitination machinery in addition to spartin is unknown. A functional ubiquitination complex is

supported by data showing that purified buoyant fractions enriched in LDs contained polyubiquitinated proteins and exhibited activity in an *in vitro* ubiquitination assay [83]. However, buoyant fractions are heavily contaminated with ER, raising the possibility that ubiquitination machinery associated with ER and not LD was the source of the observed activity. Thus, identification of ubiquitinated proteins at LDs and an understanding of how the ubiquitination machinery is regulated are important future research directions.

3.3. A role for LDs in the degradation of non-LD proteins

The presence of ERAD machinery on LDs led to the hypothesis that LDs may be functionally involved in ERAD. Several models have been proposed: i) LDs function as an “escape hatch” that facilitates the dislocation of ERAD substrates from the ER [125], ii) ERAD occurs in LD-associated ER subdomains [126,127], iii) ERAD substrates transiently localize to the LD surface prior to proteasomal degradation [59,128,129]. In agreement with the potential importance of LDs for ERAD, inhibition of LD biogenesis with the long chain acyl-CoA synthetase inhibitor triacsin C stabilized several ERAD substrates in mammalian cells [87,126,127]. However, the degradation kinetics of multiple ERAD substrates were not affected in a yeast strain lacking the neutral lipid synthesis machinery necessary to make LDs [130,131]. Moreover, depletion of LDs in mammalian cells through inhibition of the TAG synthesis enzymes DGAT1 and DGAT2 also did not impair ERAD of the endogenous substrate CD147 [132]. Instead, this study found that triacsin C impaired CD147 glycan trimming [132], an early step in ERAD that results in the generation of degradation signal recognized by ERAD-implicated lectins [133,134]. Other studies have demonstrated that some ERAD substrates accumulate in LD-enriched buoyant fractions when ERAD is compromised, potentially indicating that these proteins traffic through LDs or ER-associated buoyant compartments on route to the proteasome. One such ERAD substrate is HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, which is stabilized in buoyant fractions and ER sites juxtaposed to LDs following knockdown of VCP or inhibition of the proteasome [126,127]. Interestingly, an HMG-CoA reductase lysine mutant that was resistant to ubiquitination appeared in the buoyant fraction, suggesting that trafficking into this compartment precedes its extraction by VCP into the cytosol, a step that canonically requires prior ubiquitination of the substrate [126]. Another ERAD substrate is Apolipoprotein B-100 (ApoB), a component of very low density lipoproteins (VLDL) and low density lipoproteins (LDL). ApoB was observed in a crescent-shaped compartment comprised of ER wrapped around one hemisphere of an adjoining LD in cultured hepatocellular carcinoma cells [135]. Knockdown of UBXD8 resulted in the accumulation of ApoB in crescents [59], suggesting a possible role of LD-associated UBXD8 in the degradation of ApoB from the crescent compartment. Thus, although LDs are not fundamentally required for ERAD, a subset of ERAD substrates may transit through compartments that are in close proximity to LDs prior to undergoing proteolysis by cytosolic proteasomes. However, the precise requirement for these compartments in ERAD has not been established.

3.4. Degradation-independent roles for ubiquitination on LDs

Several studies raise the possibility that ubiquitin may have roles on LDs independent of protein degradation [112]. Ubiquitin can mediate interactions with proteins containing

ubiquitin-binding domains (e.g. CUE, UBA, and UIM domains), such as AUP1, which contains a CUE domain [87,136]. AUP1 was also found to be monoubiquitinated and diubiquitinated (or monoubiquitinated on multiple lysines) [87,136]. Interestingly, overexpression of AUP1 was sufficient to induce LD clustering [136]. The clustering phenotype was dependent on the ubiquitination status of AUP1, since overexpression of a CUE domain mutant that was not ubiquitinated did not induce clustering, but fusion of this mutant to ubiquitin at its C-terminus rescued AUP1-induced clustering [136]. Similarly, ubiquitination of *Drosophila* LD protein CG9186 in Kc167 cells was required for LD clustering induced by CG9186 overexpression [137,138]. A model that explains the clustering phenotype observed in these studies is that ubiquitinated AUP1 or CG9186 promotes the formation of ubiquitin-dependent homo- or hetero-dimers that bridge adjacent LDs. The physiological importance of the clustering phenomenon is unclear, but it has been suggested that LD clustering precedes LD fusion [136,139,140].

LD-associated VCP may also function outside of its well characterized role in ERAD [141]. VCP, and its yeast ortholog CDC48, also mediate the disassembly of ubiquitinated protein complexes [141–143]. Interestingly, depletion of the VCP adaptor UBXD8 from LD increased the association of ATGL with its activator CGI-58 [85], indicating that VCP may function in remodeling protein-protein interactions on droplets. Although ATGL is degraded by the UPS in the absence of LDs, recruitment of VCP to LDs by overexpression of UBXD8 had no effect on ATGL levels, suggesting that UBXD8 and VCP regulate the activity, but not the stability of ATGL [85]. Additional studies are needed to elucidate the role of this important protein at LDs.

4. Autophagy and LDs

4.1. Lipophagy: The selective autophagic degradation of LDs

Macroautophagy is a process that mediates the engulfment of portions of cytoplasm within double-membrane organelles called autophagosomes [144]. These organelles fuse with acidic lysosomes, forming autolysosomes that hydrolyze sequestered cytoplasmic contents [144]. Lipophagy refers to the selective autophagic degradation of LDs, which leads to degradation of LD lipids and proteins. Lipophagy has been recently reviewed [145–148] and is beyond the scope of this review. Here, we will focus on autophagic mechanisms that govern the targeted clearance of select LD proteins.

4.2. Chaperone-mediated autophagy of select LD proteins

Chaperone-mediated autophagy (CMA) mediates the delivery of a subset of proteins bearing a pentapeptide motif (KFERQ or a related sequence) to the lysosome for degradation. In this process, heat shock cognate protein of 70 kDa (hsc70) recognizes and delivers the substrate to the lysosome-associated membrane protein 2A (LAMP-2A), which forms a multimeric complex that transports unfolded substrates into the lysosome lumen for degradation. Mice lacking LAMP-2A exhibit defects in CMA and have profound accumulation of fat in the liver [149,150], suggesting that CMA controls lipid metabolism. Interestingly, CMA motifs were identified in PLIN2 (LDRLQ) and PLIN3 (SLKVQ), and both proteins were degraded in mouse embryonic fibroblasts through a pathway that required hsc70 and LAMP-2A [150].

Furthermore, mutation of the CMA motif in PLIN2 impaired binding of hsc70 to PLIN2 and increased its steady state levels [150]. Disruptions in CMA-mediated degradation of PLIN2 and PLIN3 reduced LD degradation through both ATGL-dependent lipolysis and macroautophagy [150], suggesting that the removal of perilipins by CMA increases lipolysis of lipid stores by ATGL in LDs and increases recognition of LDs by autophagic machinery. This is consistent with a previous finding that PLIN2 can compete with ATGL for binding to LDs [151]. Interestingly, PLIN2 phosphorylation by AMP-activated protein kinase (AMPK) may prime PLIN2 for degradation by CMA, coupling the degradation of this important regulator of LD function to the energy status of the cell [150,152].

5. Perspectives and conclusions

LDs contain a unique proteome that places this organelle at the center of cellular lipid and energy homeostasis. In recent years, many studies have attempted to answer questions regarding how the LD proteome is established and regulated. Bioinformatics approaches have not been successful at predicting which proteins are targeted to LDs and new empirical approaches are still under development. However, general mechanisms based on membrane biophysics and the types of monotopic conformations that can be accommodated within monolayers have now become appreciated. Likewise, the mechanisms that regulate the abundance of LD proteins are complex, likely involving multiple UPS pathways in separate subcellular compartments as well as autophagic pathways. Our understanding of these pathways is still in its infancy and many questions remain as to the nature of the degradation signals presented by the substrates, the identities of the ubiquitination components within the degradation pathways, and the regulation of these pathways in different cell types and under different metabolic states. Ultimately, a comprehensive understanding of how the LD proteome composition is established is essential to elucidate the role of LDs in human disease. This understanding will require extensive research into the regulation of LD protein targeting and clearance.

Acknowledgments

This work was supported by grants from the National Institutes of Health (R01GM112948) and the American Heart Association (16GRNT30870005). We thank Bianca Schrul, Milton To, and Camille Pataki for critical reading of this manuscript.

References

1. Walther TC, Farese RV. Lipid droplets and cellular lipid metabolism. *Annu Rev Biochem.* 2012; 81:687–714. DOI: 10.1146/annurev-biochem-061009-102430 [PubMed: 22524315]
2. Pol A, Gross SP, Parton RG. Review: biogenesis of the multifunctional lipid droplet: lipids, proteins, and sites. *J Cell Biol.* 2014; 204:635–646. DOI: 10.1083/jcb.201311051 [PubMed: 24590170]
3. Hashemi HF, Goodman JM. The life cycle of lipid droplets. *Curr Opin Cell Biol.* 2015; 33:119–124. DOI: 10.1016/j.ceb.2015.02.002 [PubMed: 25703629]
4. Gao Q, Goodman JM. The lipid droplet-a well-connected organelle. *Front Cell Dev Biol.* 2015; 3:49.doi: 10.3389/fcell.2015.00049 [PubMed: 26322308]
5. Listenberger LL, Han X, Lewis SE, Cases S, Farese RV, Ory DS, et al. Triglyceride accumulation protects against fatty acid-induced lipotoxicity. *Proc Natl Acad Sci U S A.* 2003; 100:3077–3082. DOI: 10.1073/pnas.0630588100 [PubMed: 12629214]

6. Bailey AP, Koster G, Guillermier C, Hirst EMA, MacRae JI, Lechene CP, et al. Antioxidant Role for Lipid Droplets in a Stem Cell Niche of *Drosophila*. *Cell*. 2015; 163:340–353. DOI: 10.1016/j.cell.2015.09.020 [PubMed: 26451484]
7. Rambold AS, Cohen S, Lippincott-Schwartz J. Fatty acid trafficking in starved cells: regulation by lipid droplet lipolysis, autophagy, and mitochondrial fusion dynamics. *Dev Cell*. 2015; 32:678–692. DOI: 10.1016/j.devcel.2015.01.029 [PubMed: 25752962]
8. Herms A, Bosch M, Reddy BJN, Schieber NL, Fajardo A, Rupérez C, et al. AMPK activation promotes lipid droplet dispersion on detyrosinated microtubules to increase mitochondrial fatty acid oxidation. *Nat Commun*. 2015; 6:7176.doi: 10.1038/ncomms8176 [PubMed: 26013497]
9. Kurat CF, Wolinski H, Petschnigg J, Kaluarachchi S, Andrews B, Natter K, et al. Cdk1/Cdc28-dependent activation of the major triacylglycerol lipase Tgl4 in yeast links lipolysis to cell-cycle progression. *Mol Cell*. 2009; 33:53–63. DOI: 10.1016/j.molcel.2008.12.019 [PubMed: 19150427]
10. Gaspar ML, Hofbauer HF, Kohlwein SD, Henry SA. Coordination of storage lipid synthesis and membrane biogenesis: evidence for cross-talk between triacylglycerol metabolism and phosphatidylinositol synthesis. *J Biol Chem*. 2011; 286:1696–1708. DOI: 10.1074/jbc.M110.172296 [PubMed: 20972264]
11. Chauhan N, Visram M, Cristobal-Sarramian A, Sarkleti F, Kohlwein SD. Morphogenesis checkpoint kinase Swe1 is the executor of lipolysis-dependent cell-cycle progression. *Proc Natl Acad Sci U S A*. 2015; 112:E1077–85. DOI: 10.1073/pnas.1423175112 [PubMed: 25713391]
12. Tang T, Abbott MJ, Ahmadian M, Lopes AB, Wang Y, Sul HS. Desnutrin/ATGL activates PPAR δ to promote mitochondrial function for insulin secretion in islet β cells. *Cell Metab*. 2013; 18:883–895. DOI: 10.1016/j.cmet.2013.10.012 [PubMed: 24268737]
13. Haemmerle G, Moustafa T, Woelkart G, Büttner S, Schmidt A, van de Weijer T, et al. ATGL-mediated fat catabolism regulates cardiac mitochondrial function via PPAR- α and PGC-1. *Nat Med*. 2011; 17:1076–1085. DOI: 10.1038/nm.2439 [PubMed: 21857651]
14. Greenberg ANDREWS, Coleman ROSALINDA, Kraemer FREDRICB, McManaman JAMESL, Obin MARTINS, Puri VISHWAJEET, et al. The role of lipid droplets in metabolic disease in rodents and humans. *J Clin Invest*. 2011; 121:2102–2110. DOI: 10.1172/JCI46069 [PubMed: 21633178]
15. Krahmer N, Farese RV, Walther TC. Balancing the fat: lipid droplets and human disease. *EMBO Mol Med*. 2013; 5:973–983. DOI: 10.1002/emmm.201100671 [PubMed: 23740690]
16. Fujimoto T, Parton RG. Not just fat: the structure and function of the lipid droplet. *Cold Spring Harb Perspect Biol*. 2011; 3:doi: 10.1101/cshperspect.a004838
17. Yang L, Ding Y, Chen Y, Zhang S, Huo C, Wang Y, et al. The proteomics of lipid droplets: structure, dynamics, and functions of the organelle conserved from bacteria to humans. *J Lipid Res*. 2012; 53:1245–1253. DOI: 10.1194/jlr.R024117 [PubMed: 22534641]
18. Hodges BDM, Wu CC. Proteomic insights into an expanded cellular role for cytoplasmic lipid droplets. *J Lipid Res*. 2010; 51:262–273. DOI: 10.1194/jlr.R003582 [PubMed: 19965608]
19. Dahlhoff M, Fröhlich T, Arnold GJ, Müller U, Leonhardt H, Zouboulis CC, et al. Characterization of the sebocyte lipid droplet proteome reveals novel potential regulators of sebaceous lipogenesis. *Exp Cell Res*. 2015; 332:146–155. DOI: 10.1016/j.yexcr.2014.12.004 [PubMed: 25523620]
20. Currie E, Guo X, Christiano R, Chitraju C, Kory N, Harrison K, et al. High confidence proteomic analysis of yeast LDs identifies additional droplet proteins and reveals connections to dolichol synthesis and sterol acetylation. *J Lipid Res*. 2014; 55:1465–1477. DOI: 10.1194/jlr.M050229 [PubMed: 24868093]
21. Beilstein F, Bouchoux J, Rousset M, Demignot S. Proteomic analysis of lipid droplets from Caco-2/TC7 enterocytes identifies novel modulators of lipid secretion. *PLoS ONE*. 2013; 8:e53017.doi: 10.1371/journal.pone.0053017 [PubMed: 23301014]
22. Khan SA, Wollaston-Hayden EE, Markowski TW, Higgins L, Mashek DG. Quantitative analysis of the murine lipid droplet-associated proteome during diet-induced hepatic steatosis. *J Lipid Res*. 2015; 56:2260–2272. DOI: 10.1194/jlr.M056812 [PubMed: 26416795]
23. Saka HA, Thompson JW, Chen Y-S, Dubois LG, Haas JT, Moseley A, et al. Chlamydia trachomatis Infection Leads to Defined Alterations to the Lipid Droplet Proteome in Epithelial Cells. *PLoS ONE*. 2015; 10:e0124630.doi: 10.1371/journal.pone.0124630 [PubMed: 25909443]

24. Bartz R, Zehmer JK, Zhu M, Chen Y, Serrero G, Zhao Y, et al. Dynamic activity of lipid droplets: protein phosphorylation and GTP-mediated protein translocation. *J Proteome Res.* 2007; 6:3256–3265. DOI: 10.1021/pr070158j [PubMed: 17608402]
25. Eichmann TO, Grumet L, Taschler U, Hartler J, Heier C, Woblistin A, et al. ATGL and CGI-58 are lipid droplet proteins of the hepatic stellate cell line HSC-T6. *J Lipid Res.* 2015; 56:1972–1984. DOI: 10.1194/jlr.M062372 [PubMed: 26330055]
26. Xie X, Yi Z, Bowen B, Wolf C, Flynn CR, Sinha S, et al. Characterization of the Human Adipocyte Proteome and Reproducibility of Protein Abundance by One-Dimensional Gel Electrophoresis and HPLC-ESI-MS/MS. *J Proteome Res.* 2010; 9:4521–4534. DOI: 10.1021/pr100268f [PubMed: 20812759]
27. Vrablik TL, Petyuk VA, Larson EM, Smith RD, Watts JL. Lipidomic and proteomic analysis of *Caenorhabditis elegans* lipid droplets and identification of ACS-4 as a lipid droplet-associated protein. *Biochim Biophys Acta.* 2015; 1851:1337–1345. DOI: 10.1016/j.bbali.2015.06.004 [PubMed: 26121959]
28. Ding Y, Wu Y, Zeng R, Liao K. Proteomic profiling of lipid droplet-associated proteins in primary adipocytes of normal and obese mouse. *Acta Biochim Biophys Sin (Shanghai).* 2012; 44:394–406. DOI: 10.1093/abbs/gms008 [PubMed: 22343379]
29. Cermelli S, Guo Y, Gross SP, Welte MA. The lipid-droplet proteome reveals that droplets are a protein-storage depot. *Curr Biol.* 2006; 16:1783–1795. DOI: 10.1016/j.cub.2006.07.062 [PubMed: 16979555]
30. Zhang H, Wang Y, Li J, Yu J, Pu J, Li L, et al. Proteome of skeletal muscle lipid droplet reveals association with mitochondria and apolipoprotein a-I. *J Proteome Res.* 2011; 10:4757–4768. DOI: 10.1021/pr200553c [PubMed: 21870882]
31. Larsson S, Resjö S, Gomez MF, James P, Holm C. Characterization of the lipid droplet proteome of a clonal insulin-producing β -cell line (INS-1 832/13). *J Proteome Res.* 2012; 11:1264–1273. DOI: 10.1021/pr200957p [PubMed: 22268682]
32. Rösch K, Kwiatkowski M, Hofmann S, Schöbel A, Grüttner C, Wurlitzer M, et al. Quantitative lipid droplet proteome analysis identifies annexin A3 as a cofactor for HCV particle production. *Cell Rep.* 2016; 16:3219–3231. DOI: 10.1016/j.celrep.2016.08.052 [PubMed: 27653686]
33. Brasaemle DL, Dolios G, Shapiro L, Wang R. Proteomic analysis of proteins associated with lipid droplets of basal and lipolytically stimulated 3T3-L1 adipocytes. *J Biol Chem.* 2004; 279:46835–46842. DOI: 10.1074/jbc.M409340200 [PubMed: 15337753]
34. Baumeier C, Kaiser D, Heeren J, Scheja L, John C, Weise C, et al. Caloric restriction and intermittent fasting alter hepatic lipid droplet proteome and diacylglycerol species and prevent diabetes in NZO mice. *Biochim Biophys Acta.* 2015; 1851:566–576. DOI: 10.1016/j.bbali.2015.01.013 [PubMed: 25645620]
35. Yu J, Zhang S, Cui L, Wang W, Na H, Zhu X, et al. Lipid droplet remodeling and interaction with mitochondria in mouse brown adipose tissue during cold treatment. *Biochim Biophys Acta.* 2015; 1853:918–928. DOI: 10.1016/j.bbamcr.2015.01.020 [PubMed: 25655664]
36. Liu P, Ying Y, Zhao Y, Mundy DI, Zhu M, Anderson RGW. Chinese hamster ovary K2 cell lipid droplets appear to be metabolic organelles involved in membrane traffic. *J Biol Chem.* 2004; 279:3787–3792. DOI: 10.1074/jbc.M311945200 [PubMed: 14597625]
37. Beller M, Riedel D, Jansch L, Dieterich G, Wehland J, Jäckle H, et al. Characterization of the *Drosophila* lipid droplet subproteome. *Mol Cell Proteomics.* 2006; 5:1082–1094. DOI: 10.1074/mcp.M600011-MCP200 [PubMed: 16543254]
38. Crunk AE, Monks J, Murakami A, Jackman M, Maclean PS, Ladinsky M, et al. Dynamic regulation of hepatic lipid droplet properties by diet. *PLoS ONE.* 2013; 8:e67631.doi: 10.1371/journal.pone.0067631 [PubMed: 23874434]
39. Khor VK, Ahrends R, Lin Y, Shen W-J, Adams CM, Roseman AN, et al. The proteome of cholesteryl-ester-enriched versus triacylglycerol-enriched lipid droplets. *PLoS ONE.* 2014; 9:e105047.doi: 10.1371/journal.pone.0105047 [PubMed: 25111084]
40. Wilfling F, Wang H, Haas JT, Krahmer N, Gould TJ, Uchida A, et al. Triacylglycerol synthesis enzymes mediate lipid droplet growth by relocalizing from the ER to lipid droplets. *Dev Cell.* 2013; 24:384–399. DOI: 10.1016/j.devcel.2013.01.013 [PubMed: 23415954]

41. Wang H, Becuwe M, Housden BE, Chitraju C, Porras AJ, Graham MM, et al. Seipin is required for converting nascent to mature lipid droplets. *Elife*. 2016; 5doi: 10.7554/eLife.16582
42. Grippa A, Buxó L, Mora G, Funaya C, Idrissi F-Z, Mancuso F, et al. The seipin complex Fld1/Ldb16 stabilizes ER-lipid droplet contact sites. *J Cell Biol*. 2015; 211:829–844. DOI: 10.1083/jcb.201502070 [PubMed: 26572621]
43. Choudhary V, Ojha N, Golden A, Prinz WA. A conserved family of proteins facilitates nascent lipid droplet budding from the ER. *J Cell Biol*. 2015; 211:261–271. DOI: 10.1083/jcb.201505067 [PubMed: 26504167]
44. Salo VT, Belevich I, Li S, Karhinen L, Vihinen H, Vigouroux C, et al. Seipin regulates ER-lipid droplet contacts and cargo delivery. *EMBO J*. 2016; 35:2699–2716. DOI: 10.15252/embj.201695170 [PubMed: 27879284]
45. Wang H, Sreenivasan U, Sreenivasan U, Hu H, Saladino A, Polster BM, et al. Perilipin 5, a lipid droplet-associated protein, provides physical and metabolic linkage to mitochondria. *J Lipid Res*. 2011; 52:2159–2168. DOI: 10.1194/jlr.M017939 [PubMed: 21885430]
46. Binns D, Januszewski T, Chen Y, Hill J, Markin VS, Zhao Y, et al. An intimate collaboration between peroxisomes and lipid bodies. *J Cell Biol*. 2006; 173:719–731. DOI: 10.1083/jcb.200511125 [PubMed: 16735577]
47. Schrader M. Tubulo-Reticular Clusters of Peroxisomes in Living COS-7 Cells: Dynamic Behavior and Association with Lipid Droplets. *Journal of Histochemistry & Cytochemistry*. 2001; 49:1421–1429. DOI: 10.1177/002215540104901110 [PubMed: 11668195]
48. Liu P, Bartz R, Zehmer JK, Ying Y, Zhu M, Serrero G, et al. Rab-regulated interaction of early endosomes with lipid droplets. *Biochim Biophys Acta*. 2007; 1773:784–793. DOI: 10.1016/j.bbamcr.2007.02.004 [PubMed: 17395284]
49. Krahmer N, Hilger M, Kory N, Wilfling F, Stoehr G, Mann M, et al. Protein correlation profiles identify lipid droplet proteins with high confidence. *Mol Cell Proteomics*. 2013; 12:1115–1126. DOI: 10.1074/mcp.M112.020230 [PubMed: 23319140]
50. Thiam AR, Beller M. The why, when and how of lipid droplet diversity. *J Cell Sci*. 2017; 130:315–324. DOI: 10.1242/jcs.192021 [PubMed: 28049719]
51. Zhang S, Wang Y, Cui L, Deng Y, Xu S, Yu J, et al. Morphologically and functionally distinct lipid droplet subpopulations. *Sci Rep*. 2016; 6:29539.doi: 10.1038/srep29539 [PubMed: 27386790]
52. Wolins NE, Quaynor BK, Skinner JR, Schoenfish MJ, Tzekov A, Bickel PE. S3–12, Adipophilin, and TIP47 package lipid in adipocytes. *J Biol Chem*. 2005; 280:19146–19155. DOI: 10.1074/jbc.M500978200 [PubMed: 15731108]
53. Kassan A, Herms A, Fernández-Vidal A, Bosch M, Schieber NL, Reddy BJN, et al. Acyl-CoA synthetase 3 promotes lipid droplet biogenesis in ER microdomains. *J Cell Biol*. 2013; 203:985–1001. DOI: 10.1083/jcb.201305142 [PubMed: 24368806]
54. Martin S, Driessen K, Nixon SJ, Zerial M, Parton RG. Regulated localization of Rab18 to lipid droplets: effects of lipolytic stimulation and inhibition of lipid droplet catabolism. *J Biol Chem*. 2005; 280:42325–42335. DOI: 10.1074/jbc.M506651200 [PubMed: 16207721]
55. Pulido MR, Diaz-Ruiz A, Jiménez-Gómez Y, García-Navarro S, Gracia-Navarro F, Tinahones F, et al. Rab18 dynamics in adipocytes in relation to lipogenesis, lipolysis and obesity. *PLoS ONE*. 2011; 6:e22931.doi: 10.1371/journal.pone.0022931 [PubMed: 21829560]
56. Hsieh K, Lee YK, Londres C, Raaka BM, Dalen KT, Kimmel AR. Perilipin family members preferentially sequester to either triacylglycerol-specific or cholesteryl-ester-specific intracellular lipid storage droplets. *J Cell Sci*. 2012; 125:4067–4076. DOI: 10.1242/jcs.104943 [PubMed: 22685330]
57. Kory N, Farese RV, Walther TC. Targeting fat: mechanisms of protein localization to lipid droplets. *Trends Cell Biol*. 2016; 26:535–546. DOI: 10.1016/j.tcb.2016.02.007 [PubMed: 26995697]
58. Lee JN, Kim H, Yao H, Chen Y, Weng K, Ye J. Identification of Ubx8 protein as a sensor for unsaturated fatty acids and regulator of triglyceride synthesis. *Proc Natl Acad Sci U S A*. 2010; 107:21424–21429. DOI: 10.1073/pnas.1011859107 [PubMed: 21115839]
59. Suzuki M, Otsuka T, Ohsaki Y, Cheng J, Taniguchi T, Hashimoto H, et al. Derlin-1 and UBXD8 are engaged in dislocation and degradation of lipidated ApoB-100 at lipid droplets. *Mol Biol Cell*. 2012; 23:800–810. DOI: 10.1091/mbc.E11-11-0950 [PubMed: 22238364]

60. Stevanovic A, Thiele C. Monotopic topology is required for lipid droplet targeting of ancient ubiquitous protein 1. *J Lipid Res.* 2013; 54:503–513. DOI: 10.1194/jlr.M033852 [PubMed: 23197321]
61. Monier S, Parton RG, Vogel F, Behlke J, Henske A, Kurzchalia TV. VIP21-caveolin, a membrane protein constituent of the caveolar coat, oligomerizes in vivo and in vitro. *Mol Biol Cell.* 1995; 6:911–927. [PubMed: 7579702]
62. Ingelmo-Torres M, González-Moreno E, Kassan A, Hanzal-Bayer M, Tebar F, Herms A, et al. Hydrophobic and basic domains target proteins to lipid droplets. *Traffic.* 2009; 10:1785–1801. DOI: 10.1111/j.1600-0854.2009.00994.x [PubMed: 19874557]
63. Stone SJ, Levin MC, Farese RV. Membrane topology and identification of key functional amino acid residues of murine acyl-CoA:diacylglycerol acyltransferase-2. *J Biol Chem.* 2006; 281:40273–40282. DOI: 10.1074/jbc.M607986200 [PubMed: 17035227]
64. Abell BM, Holbrook LA, Abenes M, Murphy DJ, Hills MJ, Moloney MM. Role of the proline knot motif in oleosin endoplasmic reticulum topology and oil body targeting. *Plant Cell.* 1997; 9:1481–1493. DOI: 10.1105/tpc.9.8.1481 [PubMed: 9286116]
65. Huang AH. Oleosins and oil bodies in seeds and other organs. *Plant Physiol.* 1996; 110:1055–1061. [PubMed: 8934621]
66. Hope RG, Murphy DJ, McLauchlan J. The domains required to direct core proteins of hepatitis C virus and GB virus-B to lipid droplets share common features with plant oleosin proteins. *J Biol Chem.* 2002; 277:4261–4270. DOI: 10.1074/jbc.M108798200 [PubMed: 11706032]
67. Aoki S, Thomas A, Decaffmeyer M, Brasseur R, Epand RM. The role of proline in the membrane re-entrant helix of caveolin-1. *J Biol Chem.* 2010; 285:33371–33380. DOI: 10.1074/jbc.M110.153569 [PubMed: 20729193]
68. Zehmer JK, Bartz R, Liu P, Anderson RGW. Identification of a novel N-terminal hydrophobic sequence that targets proteins to lipid droplets. *J Cell Sci.* 2008; 121:1852–1860. DOI: 10.1242/jcs.012013 [PubMed: 18477614]
69. Krahmer N, Guo Y, Wilfling F, Hilger M, Lingrell S, Heger K, et al. Phosphatidylcholine synthesis for lipid droplet expansion is mediated by localized activation of CTP:phosphocholine cytidyltransferase. *Cell Metab.* 2011; 14:504–515. DOI: 10.1016/j.cmet.2011.07.013 [PubMed: 21982710]
70. Guo Y, Walther TC, Rao M, Stuurman N, Goshima G, Terayama K, et al. Functional genomic screen reveals genes involved in lipid-droplet formation and utilization. *Nature.* 2008; 453:657–661. DOI: 10.1038/nature06928 [PubMed: 18408709]
71. Barneda D, Planas-Iglesias J, Gaspar ML, Mohammadyani D, Prasannan S, Dormann D, et al. The brown adipocyte protein CIDEA promotes lipid droplet fusion via a phosphatidic acid-binding amphipathic helix. *Elife.* 2015; 4:e07485.doi: 10.7554/eLife.07485 [PubMed: 26609809]
72. Rowe ER, Mimmack ML, Barbosa AD, Haider A, Isaac I, Oubrai MM, et al. Conserved Amphipathic Helices Mediate Lipid Droplet Targeting of Perilipins 1–3. *J Biol Chem.* 2016; 291:6664–6678. DOI: 10.1074/jbc.M115.691048 [PubMed: 26742848]
73. Hinson ER, Cresswell P. The antiviral protein, viperin, localizes to lipid droplets via its N-terminal amphipathic alpha-helix. *Proc Natl Acad Sci U S A.* 2009; 106:20452–20457. DOI: 10.1073/pnas.0911679106 [PubMed: 19920176]
74. Bigay J, Antonny B. Curvature, lipid packing, and electrostatics of membrane organelles: defining cellular territories in determining specificity. *Dev Cell.* 2012; 23:886–895. DOI: 10.1016/j.devcel.2012.10.009 [PubMed: 23153485]
75. Cornell RB. Membrane lipid compositional sensing by the inducible amphipathic helix of CCT. *Biochim Biophys Acta.* 2016; 1861:847–861. DOI: 10.1016/j.bbalip.2015.12.022 [PubMed: 26747646]
76. Wilfling F, Thiam AR, Olarte M-J, Wang J, Beck R, Gould TJ, et al. Arf1/COPI machinery acts directly on lipid droplets and enables their connection to the ER for protein targeting. *Elife.* 2014; 3:e01607.doi: 10.7554/eLife.01607 [PubMed: 24497546]
77. Aitchison AJ, Arsenault DJ, Ridgway ND. Nuclear-localized CTP:phosphocholine cytidyltransferase α regulates phosphatidylcholine synthesis required for lipid droplet

- biogenesis. *Mol Biol Cell*. 2015; 26:2927–2938. DOI: 10.1091/mbc.E15-03-0159 [PubMed: 26108622]
78. Henneberry AL, Wright MM, McMaster CR. The major sites of cellular phospholipid synthesis and molecular determinants of Fatty Acid and lipid head group specificity. *Mol Biol Cell*. 2002; 13:3148–3161. DOI: 10.1091/mbc.01-11-0540 [PubMed: 12221122]
 79. Kimmel AR, Sztalryd C. The Perilipins: Major Cytosolic Lipid Droplet-Associated Proteins and Their Roles in Cellular Lipid Storage, Mobilization, and Systemic Homeostasis. *Annu Rev Nutr*. 2016; 36:471–509. DOI: 10.1146/annurev-nutr-071813-105410 [PubMed: 27431369]
 80. Brasaemle DL, Barber T, Kimmel AR, Londos C. Post-translational regulation of perilipin expression. Stabilization by stored intracellular neutral lipids. *J Biol Chem*. 1997; 272:9378–9387. [PubMed: 9083075]
 81. Londos C, Brasaemle DL, Schultz CJ, Segrest JP, Kimmel AR. Perilipins, ADRP, and other proteins that associate with intracellular neutral lipid droplets in animal cells. *Semin Cell Dev Biol*. 1999; 10:51–58. DOI: 10.1006/scdb.1998.0275 [PubMed: 10355028]
 82. Takahashi Y, Shinoda A, Kamada H, Shimizu M, Inoue J, Sato R. Perilipin2 plays a positive role in adipocytes during lipolysis by escaping proteasomal degradation. *Sci Rep*. 2016; 6:20975.doi: 10.1038/srep20975 [PubMed: 26876687]
 83. Hickenbottom SJ, Kimmel AR, Londos C, Hurley JH. Structure of a lipid droplet protein; the PAT family member TIP47. *Structure*. 2004; 12:1199–1207. DOI: 10.1016/j.str.2004.04.021 [PubMed: 15242596]
 84. Suzuki M, Murakami T, Cheng J, Kano H, Fukata M, Fujimoto T. ELMOD2 is anchored to lipid droplets by palmitoylation and regulates adipocyte triglyceride lipase recruitment. *Mol Biol Cell*. 2015; 26:2333–2342. DOI: 10.1091/mbc.E14-11-1504 [PubMed: 25904333]
 85. Boström P, Andersson L, Rutberg M, Perman J, Lidberg U, Johansson BR, et al. SNARE proteins mediate fusion between cytosolic lipid droplets and are implicated in insulin sensitivity. *Nat Cell Biol*. 2007; 9:1286–1293. DOI: 10.1038/ncb1648 [PubMed: 17922004]
 86. Boeszoermenyi A, Nagy HM, Arthanari H, Pillip CJ, Lindermuth H, Luna RE, et al. Structure of a CGI-58 motif provides the molecular basis of lipid droplet anchoring. *J Biol Chem*. 2015; 290:26361–26372. DOI: 10.1074/jbc.M115.682203 [PubMed: 26350461]
 87. Klemm EJ, Spooner E, Ploegh HL. Dual role of ancient ubiquitous protein 1 (AUP1) in lipid droplet accumulation and endoplasmic reticulum (ER) protein quality control. *J Biol Chem*. 2011; 286:37602–37614. DOI: 10.1074/jbc.M111.284794 [PubMed: 21857022]
 88. Spandl J, Lohmann D, Kuerschner L, Moessinger C, Thiele C. Ancient ubiquitous protein 1 (AUP1) localizes to lipid droplets and binds the E2 ubiquitin conjugase G2 (Ube2g2) via its G2 binding region. *J Biol Chem*. 2011; 286:5599–5606. DOI: 10.1074/jbc.M110.190785 [PubMed: 21127063]
 89. Olzmann JA, Richter CM, Kopito RR. Spatial regulation of UBXD8 and p97/VCP controls ATGL-mediated lipid droplet turnover. *Proc Natl Acad Sci U S A*. 2013; 110:1345–1350. DOI: 10.1073/pnas.1213738110 [PubMed: 23297223]
 90. Shen W-J, Patel S, Miyoshi H, Greenberg AS, Kraemer FB. Functional interaction of hormone-sensitive lipase and perilipin in lipolysis. *J Lipid Res*. 2009; 50:2306–2313. DOI: 10.1194/jlr.M900176-JLR200 [PubMed: 19515989]
 91. Wang H, Hu L, Dalen K, Dorward H, Marcinkiewicz A, Russell D, et al. Activation of hormone-sensitive lipase requires two steps, protein phosphorylation and binding to the PAT-1 domain of lipid droplet coat proteins. *J Biol Chem*. 2009; 284:32116–32125. DOI: 10.1074/jbc.M109.006726 [PubMed: 19717842]
 92. Shao S, Hegde RS. Membrane protein insertion at the endoplasmic reticulum. *Annu Rev Cell Dev Biol*. 2011; 27:25–56. DOI: 10.1146/annurev-cellbio-092910-154125 [PubMed: 21801011]
 93. Hegde RS, Keenan RJ. Tail-anchored membrane protein insertion into the endoplasmic reticulum. *Nat Rev Mol Cell Biol*. 2011; 12:787–798. DOI: 10.1038/nrm3226 [PubMed: 22086371]
 94. Denic V, Dötsch V, Sinning I. Endoplasmic reticulum targeting and insertion of tail-anchored membrane proteins by the GET pathway. *Cold Spring Harb Perspect Biol*. 2013; 5:a013334.doi: 10.1101/cshperspect.a013334 [PubMed: 23906715]

95. Park E, Rapoport TA. Mechanisms of Sec61/SecY-mediated protein translocation across membranes. *Annu Rev Biophys.* 2012; 41:21–40. DOI: 10.1146/annurev-biophys-050511-102312 [PubMed: 22224601]
96. Beaudoin F, Wilkinson BM, Stirling CJ, Napier JA. In vivo targeting of a sunflower oil body protein in yeast secretory (sec) mutants. *Plant J.* 2000; 23:159–170. DOI: 10.1046/j.1365-313x.2000.00769.x [PubMed: 10929110]
97. Schrul B, Kopito RR. Peroxin-dependent targeting of a lipid-droplet-destined membrane protein to ER subdomains. *Nat Cell Biol.* 2016; 18:740–751. DOI: 10.1038/ncb3373 [PubMed: 27295553]
98. Mayerhofer PU. Targeting and insertion of peroxisomal membrane proteins: ER trafficking versus direct delivery to peroxisomes. *Biochim Biophys Acta.* 2016; 1863:870–880. DOI: 10.1016/j.bbamcr.2015.09.021 [PubMed: 26392202]
99. Vastiau IMK, Anthonio EA, Brams M, Brees C, Young SG, Van de Velde S, et al. Farnesylation of Pex19p is not essential for peroxisome biogenesis in yeast and mammalian cells. *Cell Mol Life Sci.* 2006; 63:1686–1699. DOI: 10.1007/s00018-006-6110-y [PubMed: 16791427]
100. Rucktäschel R, Thoms S, Sidorovitch V, Halbach A, Pechlivanis M, Volkmer R, et al. Farnesylation of pex19p is required for its structural integrity and function in peroxisome biogenesis. *J Biol Chem.* 2009; 284:20885–20896. DOI: 10.1074/jbc.M109.016584 [PubMed: 19451657]
101. Aviram N, Ast T, Costa EA, Arakel EC, Chuartzman SG, Jan CH, et al. The SND proteins constitute an alternative targeting route to the endoplasmic reticulum. *Nature.* 2016; 540:134–138. DOI: 10.1038/nature20169 [PubMed: 27905431]
102. Hu Q, Milenkovic L, Jin H, Scott MP, Nachury MV, Spiliotis ET, et al. A septin diffusion barrier at the base of the primary cilium maintains ciliary membrane protein distribution. *Science.* 2010; 329:436–439. DOI: 10.1126/science.1191054 [PubMed: 20558667]
103. Ungricht R, Kutay U. Mechanisms and functions of nuclear envelope remodelling. *Nat Rev Mol Cell Biol.* 2017; doi: 10.1038/nrm.2016.153
104. Szymanski KM, Binns D, Bartz R, Grishin NV, Li W-P, Agarwal AK, et al. The lipodystrophy protein seipin is found at endoplasmic reticulum lipid droplet junctions and is important for droplet morphology. *Proc Natl Acad Sci U S A.* 2007; 104:20890–20895. DOI: 10.1073/pnas.0704154104 [PubMed: 18093937]
105. Zehmer JK, Bartz R, Bisel B, Liu P, Seemann J, Anderson RGW. Targeting sequences of UBXD8 and AAM-B reveal that the ER has a direct role in the emergence and regression of lipid droplets. *J Cell Sci.* 2009; 122:3694–3702. DOI: 10.1242/jcs.054700 [PubMed: 19773358]
106. Ruggiano A, Mora G, Buxó L, Carvalho P. Spatial control of lipid droplet proteins by the ERAD ubiquitin ligase Doa10. *EMBO J.* 2016; 35:1644–1655. DOI: 10.15252/embj.201593106 [PubMed: 27357570]
107. Choi K, Kim H, Kang H, Lee S-Y, Lee SJ, Back SH, et al. Regulation of diacylglycerol acyltransferase 2 protein stability by gp78-associated endoplasmic-reticulum-associated degradation. *FEBS J.* 2014; 281:3048–3060. DOI: 10.1111/febs.12841 [PubMed: 24820123]
108. Buchberger A, Bukau B, Sommer T. Protein quality control in the cytosol and the endoplasmic reticulum: brothers in arms. *Mol Cell.* 2010; 40:238–252. DOI: 10.1016/j.molcel.2010.10.001 [PubMed: 20965419]
109. Stevenson J, Huang EY, Olzmann JA. Endoplasmic Reticulum-Associated Degradation and Lipid Homeostasis. *Annu Rev Nutr.* 2016; doi: 10.1146/annurev-nutr-071715-051030
110. Christianson JC, Ye Y. Cleaning up in the endoplasmic reticulum: ubiquitin in charge. *Nat Struct Mol Biol.* 2014; 21:325–335. DOI: 10.1038/nsmb.2793 [PubMed: 24699081]
111. Hegde RS, Ploegh HL. Quality and quantity control at the endoplasmic reticulum. *Curr Opin Cell Biol.* 2010; 22:437–446. DOI: 10.1016/j.ceb.2010.05.005 [PubMed: 20570125]
112. Komander D, Rape M. The ubiquitin code. *Annu Rev Biochem.* 2012; 81:203–229. DOI: 10.1146/annurev-biochem-060310-170328 [PubMed: 22524316]
113. Xu G, Sztalryd C, Londos C. Degradation of perilipin is mediated through ubiquitination-proteasome pathway. *Biochim Biophys Acta.* 2006; 1761:83–90. DOI: 10.1016/j.bbailip.2005.12.005 [PubMed: 16448845]

114. Xu G, Sztalryd C, Lu X, Tansey JT, Gan J, Dorward H, et al. Post-translational regulation of adipose differentiation-related protein by the ubiquitin/proteasome pathway. *J Biol Chem.* 2005; 280:42841–42847. DOI: 10.1074/jbc.M506569200 [PubMed: 16115879]
115. Ghosh M, Niyogi S, Bhattacharyya M, Adak M, Nayak DK, Chakrabarti S, et al. Ubiquitin ligase COP1 controls hepatic fat metabolism by targeting ATGL for degradation. *Diabetes.* 2016; 65:3561–3572. DOI: 10.2337/db16-0506 [PubMed: 27658392]
116. Nian Z, Sun Z, Yu L, Toh SY, Sang J, Li P. Fat-specific protein 27 undergoes ubiquitin-dependent degradation regulated by triacylglycerol synthesis and lipid droplet formation. *J Biol Chem.* 2010; 285:9604–9615. DOI: 10.1074/jbc.M109.043786 [PubMed: 20089860]
117. Zhang X, Heckmann BL, Xie X, Saarinen AM, Liu J. Regulation of FSP27 protein stability by AMPK and HSC70. *Am J Physiol Endocrinol Metab.* 2014; 307:E1047–56. DOI: 10.1152/ajpendo.00125.2014 [PubMed: 25315694]
118. Heckmann BL, Zhang X, Saarinen AM, Liu J. Regulation of G0/G1 switch gene 2 (G0S2) protein ubiquitination and stability by triglyceride accumulation and ATGL interaction. *PLoS ONE.* 2016; 11:e0156742.doi: 10.1371/journal.pone.0156742 [PubMed: 27248498]
119. Kory N, Thiam AR, Farese RV, Walther TC. Protein crowding is a determinant of lipid droplet protein composition. *Dev Cell.* 2015; 34:351–363. DOI: 10.1016/j.devcel.2015.06.007 [PubMed: 26212136]
120. Patel S, Yang W, Kozusko K, Saudek V, Savage DB. Perilipins 2 and 3 lack a carboxy-terminal domain present in perilipin 1 involved in sequestering ABHD5 and suppressing basal lipolysis. *Proc Natl Acad Sci U S A.* 2014; 111:9163–9168. DOI: 10.1073/pnas.1318791111 [PubMed: 24927580]
121. Hooper C, Puttamadappa SS, Loring Z, Shekhtman A, Bakowska JC. Spartin activates atrophin-1-interacting protein 4 (AIP4) E3 ubiquitin ligase and promotes ubiquitination of adipophilin on lipid droplets. *BMC Biol.* 2010; 8:72.doi: 10.1186/1741-7007-8-72 [PubMed: 20504295]
122. Edwards TL, Clowes VE, Tsang HTH, Connell JW, Sanderson CM, Luzio JP, et al. Endogenous spartin (SPG20) is recruited to endosomes and lipid droplets and interacts with the ubiquitin E3 ligases AIP4 and AIP5. *Biochem J.* 2009; 423:31–39. DOI: 10.1042/BJ20082398 [PubMed: 19580544]
123. Eastman SW, Yassaee M, Bieniasz PD. A role for ubiquitin ligases and Spartin/SPG20 in lipid droplet turnover. *J Cell Biol.* 2009; 184:881–894. DOI: 10.1083/jcb.200808041 [PubMed: 19307600]
124. Christianson JC, Olzmann JA, Shaler TA, Sowa ME, Bennett EJ, Richter CM, et al. Defining human ERAD networks through an integrative mapping strategy. *Nat Cell Biol.* 2012; 14:93–105. DOI: 10.1038/ncb2383
125. Ploegh HL. A lipid-based model for the creation of an escape hatch from the endoplasmic reticulum. *Nature.* 2007; 448:435–438. DOI: 10.1038/nature06004 [PubMed: 17653186]
126. Jo Y, Hartman IZ, DeBose-Boyd RA. Ancient ubiquitous protein-1 mediates sterol-induced ubiquitination of 3-hydroxy-3-methylglutaryl CoA reductase in lipid droplet-associated endoplasmic reticulum membranes. *Mol Biol Cell.* 2013; 24:169–183. DOI: 10.1091/mbc.E12-07-0564 [PubMed: 23223569]
127. Hartman IZ, Liu P, Zehmer JK, Luby-Phelps K, Jo Y, Anderson RGW, et al. Sterol-induced dislocation of 3-hydroxy-3-methylglutaryl coenzyme A reductase from endoplasmic reticulum membranes into the cytosol through a subcellular compartment resembling lipid droplets. *J Biol Chem.* 2010; 285:19288–19298. DOI: 10.1074/jbc.M110.134213 [PubMed: 20406816]
128. Vevea JD, Garcia EJ, Chan RB, Zhou B, Schultz M, Di Paolo G, et al. Role for lipid droplet biogenesis and microlipophagy in adaptation to lipid imbalance in yeast. *Dev Cell.* 2015; 35:584–599. DOI: 10.1016/j.devcel.2015.11.010 [PubMed: 26651293]
129. Ohsaki Y, Cheng J, Fujita A, Tokumoto T, Fujimoto T. Cytoplasmic lipid droplets are sites of convergence of proteasomal and autophagic degradation of apolipoprotein B. *Mol Biol Cell.* 2006; 17:2674–2683. DOI: 10.1091/mbc.E05-07-0659 [PubMed: 16597703]
130. Nakatsukasa K, Kamura T. Subcellular Fractionation Analysis of the Extraction of Ubiquitinated Polytopic Membrane Substrate during ER-Associated Degradation. *PLoS ONE.* 2016; 11:e0148327.doi: 10.1371/journal.pone.0148327 [PubMed: 26849222]

131. Olzmann JA, Kopito RR. Lipid droplet formation is dispensable for endoplasmic reticulum-associated degradation. *J Biol Chem*. 2011; 286:27872–27874. DOI: 10.1074/jbc.C111.266452 [PubMed: 21693705]
132. To M, Peterson CWH, Roberts MA, Counihan JL, Wu TT, Forster MS, et al. Lipid disequilibrium disrupts ER proteostasis by impairing ERAD substrate glycan trimming and dislocation. *Mol Biol Cell*. 2017; 28:270–284. DOI: 10.1091/mbc.E16-07-0483 [PubMed: 27881664]
133. Tyler RE, Pearce MM, Shaler TA, Olzmann JA, Greenblatt EJ, Kopito RR. Unassembled CD147 is an endogenous endoplasmic reticulum-associated degradation substrate. *Mol Biol Cell*. 2012; 23:4668–4678. DOI: 10.1091/mbc.E12-06-0428 [PubMed: 23097496]
134. Xu C, Ng DT. Glycosylation-directed quality control of protein folding. *Nat Rev Mol Cell Biol*. 2015; 16:742–752. DOI: 10.1038/nrm4073 [PubMed: 26465718]
135. Ohsaki Y, Cheng J, Suzuki M, Fujita A, Fujimoto T. Lipid droplets are arrested in the ER membrane by tight binding of lipidated apolipoprotein B-100. *J Cell Sci*. 2008; 121:2415–2422. DOI: 10.1242/jcs.025452 [PubMed: 18577578]
136. Lohmann D, Spandl J, Stevanovic A, Schoene M, Philippou-Massier J, Thiele C. Monoubiquitination of ancient ubiquitous protein 1 promotes lipid droplet clustering. *PLoS ONE*. 2013; 8:e72453.doi: 10.1371/journal.pone.0072453 [PubMed: 24039768]
137. Thiel K, Heier C, Haberl V, Thul PJ, Oberer M, Lass A, et al. The evolutionarily conserved protein CG9186 is associated with lipid droplets, required for their positioning and for fat storage. *J Cell Sci*. 2013; 126:2198–2212. DOI: 10.1242/jcs.120493 [PubMed: 23525007]
138. Kolkhof P, Werthebach M, van de Venn A, Poschmann G, Chen L, Welte M, et al. A Luciferase-fragment Complementation Assay to Detect Lipid Droplet-associated Protein-Protein Interactions. *Mol Cell Proteomics*. 2017; 16:329–345. DOI: 10.1074/mcp.M116.061499 [PubMed: 27956707]
139. Jambunathan S, Yin J, Khan W, Tamori Y, Puri V. FSP27 promotes lipid droplet clustering and then fusion to regulate triglyceride accumulation. *PLoS ONE*. 2011; 6:e28614.doi: 10.1371/journal.pone.0028614 [PubMed: 22194867]
140. Ariotti N, Murphy S, Hamilton NA, Wu L, Green K, Schieber NL, et al. Postlipolytic insulin-dependent remodeling of micro lipid droplets in adipocytes. *Mol Biol Cell*. 2012; 23:1826–1837. DOI: 10.1091/mbc.E11-10-0847 [PubMed: 22456503]
141. Meyer H, Bug M, Bremer S. Emerging functions of the VCP/p97 AAA-ATPase in the ubiquitin system. *Nat Cell Biol*. 2012; 14:117–123. DOI: 10.1038/ncb2407 [PubMed: 22298039]
142. Rape M, Hoppe T, Gorr I, Kalocay M, Richly H, Jentsch S. Mobilization of processed, membrane-tethered SPT23 transcription factor by CDC48(UFD1/NPL4), a ubiquitin-selective chaperone. *Cell*. 2001; 107:667–677. DOI: 10.1016/S0092-8674(01)00595-5 [PubMed: 11733065]
143. Ramanathan HN, Ye Y. The p97 ATPase associates with EEA1 to regulate the size of early endosomes. *Cell Res*. 2012; 22:346–359. DOI: 10.1038/cr.2011.80 [PubMed: 21556036]
144. Yang Z, Klionsky DJ. Mammalian autophagy: core molecular machinery and signaling regulation. *Curr Opin Cell Biol*. 2010; 22:124–131. DOI: 10.1016/j.ceb.2009.11.014 [PubMed: 20034776]
145. Martinez-Lopez N, Singh R. Autophagy and Lipid Droplets in the Liver. *Annu Rev Nutr*. 2015; 35:215–237. DOI: 10.1146/annurev-nutr-071813-105336 [PubMed: 26076903]
146. Ward C, Martinez-Lopez N, Otten EG, Carroll B, Maetzel D, Singh R, et al. Autophagy, lipophagy and lysosomal lipid storage disorders. *Biochim Biophys Acta*. 2016; 1861:269–284. DOI: 10.1016/j.bbalip.2016.01.006 [PubMed: 26778751]
147. Cingolani F, Czaja MJ. Regulation and functions of autophagic lipolysis. *Trends Endocrinol Metab*. 2016; 27:696–705. DOI: 10.1016/j.tem.2016.06.003 [PubMed: 27365163]
148. Wang C-W. Lipid droplets, lipophagy, and beyond. *Biochim Biophys Acta*. 2016; 1861:793–805. DOI: 10.1016/j.bbalip.2015.12.010 [PubMed: 26713677]
149. Schneider JL, Suh Y, Cuervo AM. Deficient chaperone-mediated autophagy in liver leads to metabolic dysregulation. *Cell Metab*. 2014; 20:417–432. DOI: 10.1016/j.cmet.2014.06.009 [PubMed: 25043815]

150. Kaushik S, Cuervo AM. Degradation of lipid droplet-associated proteins by chaperone-mediated autophagy facilitates lipolysis. *Nat Cell Biol.* 2015; 17:759–770. DOI: 10.1038/ncb3166 [PubMed: 25961502]
151. Listenberger LL, Ostermeyer-Fay AG, Goldberg EB, Brown WJ, Brown DA. Adipocyte differentiation-related protein reduces the lipid droplet association of adipose triglyceride lipase and slows triacylglycerol turnover. *J Lipid Res.* 2007; 48:2751–2761. DOI: 10.1194/jlr.M700359-JLR200 [PubMed: 17872589]
152. Kaushik S, Cuervo AM. AMPK-dependent phosphorylation of lipid droplet protein PLIN2 triggers its degradation by CMA. *Autophagy.* 2016; 12:432–438. DOI: 10.1080/15548627.2015.1124226 [PubMed: 26902588]
153. Masuda Y, Itabe H, Odaki M, Hama K, Fujimoto Y, Mori M, et al. ADRP/adipophilin is degraded through the proteasome-dependent pathway during regression of lipid-storing cells. *J Lipid Res.* 2006; 47:87–98. DOI: 10.1194/jlr.M500170-JLR200 [PubMed: 16230742]
154. Dai Z, Qi W, Li C, Lu J, Mao Y, Yao Y, et al. Dual regulation of adipose triglyceride lipase by pigment epithelium-derived factor: a novel mechanistic insight into progressive obesity. *Mol Cell Endocrinol.* 2013; 377:123–134. DOI: 10.1016/j.mce.2013.07.001 [PubMed: 23850519]
155. Yang X, Zhang X, Heckmann BL, Lu X, Liu J. Relative contribution of adipose triglyceride lipase and hormone-sensitive lipase to tumor necrosis factor- α (TNF- α)-induced lipolysis in adipocytes. *J Biol Chem.* 2011; 286:40477–40485. DOI: 10.1074/jbc.M111.257923 [PubMed: 21969372]

Highlights

- Lipid droplet function is inherently connected to its proteome composition
- Proteins target to lipid droplets from the ER and cytoplasm
- Proteins employ multiple mechanisms for lipid droplet association
- A diffusion barrier contributes to lipid droplet protein sorting in the ER
- Lipid droplet proteins can be degraded by the proteasome and by autophagy

Fig. 1.

The LD proteome: Structural features and targeting pathways. Proteins utilize a variety of mechanisms for association with LDs, including insertion into the membrane via hydrophobic hairpin structures (Class I), amphipathic helices (Class II), association with the membrane via lipid modifications, and indirect recruitment via interactions with integral proteins. Class I proteins insert into the ER and are subsequently trafficked to LDs.

Fig. 2.

Mechanisms of LD protein insertion into the ER and ER-LD protein sorting. (A) Two pathways have been implicated in the insertion of Class I LD proteins into the ER. The canonical SRP-Sec61 pathway (*red box*) mediates the insertion of caveolin-1 and oleosin. In this pathway, SRP recognizes the hydrophobic region as it emerges from the ribosome and translation is stalled. SRP docks with the ER-resident SRP receptor, facilitating ribosome association with the Sec61 translocon, and the proteins are cotranslationally inserted into the ER. (B) The PEX19-PEX3 pathway (*blue box*) mediates the insertion of UBXD8. PEX19

binds the hydrophobic hairpin region of UBXD8. Through association with its receptor PEX3, farnesylated PEX19 then mediates the posttranslational insertion of UBXD8 into discrete ER subdomains. (C) Multiple mechanisms contribute to the sorting of ER and LD proteomes, including 1) a topology-selective diffusion barrier formed by the junction of the LD monolayer and the ER bilayer membranes, 2) protein interactions with ER-resident proteins, which function as tethers and impact ER motility, 3) protein domains that have an inherent preference for the LD monolayer, and 4) instability in the ER, facilitating enrichment in LDs.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Fig. 3. Potential routes for LD protein degradation by the ubiquitin-proteasome system. Emerging evidence suggests that LD proteins (*shown in green*) can be degraded by multiple ubiquitin-proteasome pathways under different conditions. In the absence of LDs, LD proteins are likely degraded by both ER ubiquitination pathways (i.e. ERAD) and cytosolic ubiquitination pathways. The presence of LD-localized ubiquitination components suggests the existence of a LD-associated ubiquitination pathway.

Table 1

LD proteins degraded by the ubiquitin-proteasome system

Protein	Function	Cell type	Reference
PLIN1	Scaffold	CHO	[113]
PLIN2	Scaffold	Adipocytes differentiated from MEFs, 3T3-L1 adipocytes, CHO, HeLa, Huh7	[82,114,123,153]
CIDEA (FSP27)	LD fusion	3T3-L1 adipocytes, HEK293T	[116,117]
DGAT2	Diacylglycerol acyltransferase	HEK293, HEK293T, Huh7	[107]
ATGL	Triacylglycerol lipase	HEK293, HepG2, 3T3-L1 adipocytes	[89,115,154]
CGI-58	ATGL activator	COS7	[120]
GOS2	ATGL inhibitor	HeLa, 3T3-L1 adipocytes	[118,155]

Table 2

LD-localized ubiquitination machinery

Protein	Function	Cell type	Reference
AUP1	Ubiquitin binding, UBE2G2 recruitment	A431, Huh7, MDCK, COS7, HeLa, astrocytoma, CHO-7, SV-589	[60,87,88,126,136]
UBE2G2	E2 ubiquitin-conjugating enzyme	COS7, SV-589, CHO-K1	[87,88]
UBXD2	VCP recruitment	Huh7	[59]
UBXD8	VCP recruitment	HeLa, Huh7, NRK	[59,89,97,105]
VCP	AAA ATPase	HeLa, Huh7	[59,89]
Spartin	AIP4/AIP5 recruitment	HeLa	[121–123]
AIP4	E3 ubiquitin-protein ligase	HeLa	[121,122]
AIP5	E3 ubiquitin-protein ligase	HeLa	[122,123]